FDA accepts Nektar's constipation drug for review

11/19/2013 | American City Business Journals

The FDA has agreed to review Nektar Therapeutics' new drug application for naloxegol as a treatment for opioid-induced constipation. Naloxegol is intended for patients with chronic non-cancer pain who regularly take opioid painkillers. The move triggers a $70 million milestone fee from partner AstraZeneca.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT